Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
Date:12/7/2007

Data on Perifosine in the Treatment of Patients with Relapsed/Refractory

Multiple Myeloma to be presented on Saturday, December 8th at 5:30pm

NEW YORK, Dec. 7 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that abstracts related to KRX-0401 (Perifosine) have been selected for presentation during the poster sessions scheduled to take place at the upcoming American Society Hematology Meeting and exposition taking place at the Georgia World Congress Center in Atlanta, Georgia (December 8-11, 2007).

Copies of these abstracts, which highlight the observed clinical activity of KRX-0401 in the treatment of patients with relapsed/refractory multiple myeloma are currently available and can be viewed on-line through the ASH website: http://www.abstracts2view.com/hem07/

The following abstracts will be presented on Saturday, December 8, 2007 at 5:30pm:

[1164] - Board #318-I

Multi-Center Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (dex) for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Promising Activity as Combination Therapy with Manageable Toxicity.

Paul Richardson, S. Lonial, A. Jakubowiak, A. Krishnan, J. Wolf, J. Densmore, S. Singhal, I. Ghobrial, J. Stephenson, J. Mehta, K. Colson, D. Francis, T. Kendall, N. Obadike, K. Sullivan, J. Martin, T. Hideshima, L. Lai, P. Sportelli, L. Gardner, R. Birch, I.C. Henderson, K. Anderson

[1169] - Board #323-I

A Multiple Myeloma Research Consortium (MMRC) Multicenter Phase I Trial of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (MM): Updated Results.

Andrzej Jakubowiak, Todd Zimmerman, Melissa Alsina, Paul Richardson, Jonathan Kaufman, T. Kendall, C. Brozo, A. McAllister, C. Leister, T. Hideshima, P. Sportelli, L. Gardner, R. Birch, I.C. Henderson, K. Giusti, Kenneth Anderson

[1170*] - Board #324-I

Phase I/II Report from a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Previously Treated with Bortezomib.

Paul Richardson, A. Jakubowiak, J. Wolf, J. Allerton, J. Zonder, S. Lonial, A. Krishnan, J. Densmore, I. Ghobrial, K. Colson, T. Kendall, C. Leister, B. Martineau, T. Hideshima, T. Facon, P. Sportelli, L. Gardner, R. Birch, I.C. Henderson, K. Anderson

* Data reflected in Abstract 1170 is updated on Poster Board #324-1

Perifosine (KRX-0401) Mechanism of Action and Profile

Perifosine has been shown to inhibit or otherwise modify signaling through a number of different signal transduction pathways including Akt, MAPK, and JNK. Akt isoforms have been found to be overexpressed in renal, breast, prostate, and pancreatic cancers. Elevated levels of pAkt have been correlated with poor prognosis in patients with gastric, hepatocellular, endometrial, prostate, renal cell and head and neck cancers, as well as glioblastoma. The majority of tumors expressing high levels of pAkt were high-grade, advanced stage or had other features associated with poor prognosis.

The effects of perifosine on Akt are of particular interest because of 1) the importance of this pathway in the development of most cancers; 2) the evidence that it is often activated in tumors that are resistant to other forms of anticancer therapy; and 3) and the difficulty encountered thus far in the discovery of drugs that will inhibit this pathway without causing excessive toxicity.

To date, over 1,500 patients have been treated with perifosine in trials conducted both in the US and Europe. Its safety profile is distinctly different from that of most cytotoxic agents. It does not cause myelosuppression (depression of the immune system) or alopecia (hair loss) like many currently available treatments for cancer. In phase I/II trials it has induced tumor regressions and/or caused disease stabilization in a variety of tumor types. Responding patients, including stable disease, have been treated for months to almost 3 years, on both the daily and weekly schedule.

KRX-0401 (perifosine) is in-licensed by Keryx from Aeterna Zentaris, Inc. (Nasdaq: AEZS; TSX: AEZ) in the United States, Canada and Mexico.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx's lead compound under development is Sulonex(TM) (sulodexide oral gelcap), previously referred to as KRX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. Sulonex is in a pivotal Phase 3 and Phase 4 clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Keryx is developing Zerenex(TM), an oral, iron- based compound that has the capacity to bind phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated serum phosphorous levels) in patients with end-stage renal disease. Keryx is also developing clinical-stage oncology compounds, including KRX-0401, a novel, first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth, and a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. Keryx also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future the financial performance and clinical and business prospects for KRX-0401, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully complete the Phase 1 and Phase 2 clinical trials for KRX-0401; we may not be able to meet anticipated development timelines for KRX-0401 due to recruitment, clinical trial results, manufacturing capabilities or other factors; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.

KERYX CONTACT:

Lauren Fischer

Director - Investor Relations

Keryx Biopharmaceuticals, Inc.

Tel: 212.531.5965

E-mail: lfischer@keryx.com


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
2. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
3. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
4. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
5. HEI, Inc. Announces Sale of RFID Division Assets
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
8. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
9. Brooke Franchise Corporation Announces Selected July Results
10. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... Sideline Products participated in the World Horse Expo ... Tom Seay and his production crew. Tom Seay’s program “Best of America by ... Saddle Sidekicks will be featured on April 6, 2017. After the broadcast, the ...
(Date:2/22/2017)... ... February 22, 2017 , ... ANGLESTRONG , the new ... now available on the App Store and Google Play . Florida-based ... the addiction and recovery industry, partnered with Angle to build ANGLESTRONG. The new recovery ...
(Date:2/22/2017)... ... , ... A product of digesting a micronutrient found in soy may hold ... soy foods, while others do not, a University of Pittsburgh Graduate School of Public ... made by some types of “good” gut bacteria when they metabolize isoflavones (micronutrients found ...
(Date:2/22/2017)... ... , ... Super-Sod will attend the Athens Home Show with a brand new ... from Super-Sod’s simple Athens Home Show booth of 2016, this year’s exhibit space includes ... Chris Roquemore constructed furniture from recycled pallet wood at the Super-Sod farm in Fort ...
(Date:2/22/2017)... ... ... BrightStar Care Charleston , a home care and medical staffing agency, will ... on Aging’s Senior Expo on Thursday, March 23, 2017, at the Omar Convention ... our community. We are thrilled to participate in this event because we believe it ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... , February 22, 2017 ... the Dow Jones Industrial Average, and the S&P ... out of nine sectors ended Tuesday,s trading session ... sentiment, Stock-Callers.com assessed the following Medical Instruments & ... (NASDAQ: TNDM), C. R. Bard Inc. (NYSE: BCR), ...
(Date:2/22/2017)... Calif. , Feb. 22, 2017  Bioness, Inc., ... therapies, today announced the first series of successful StimRouter ... at Radboud University Medical Center (Nijmegen, Netherlands ... ( Cork, Ireland ), and Kliniek Park ... the successful launch continuing, Bioness plans to further support ...
(Date:2/22/2017)... PUNE, India , February 22, 2017 According ... (Spectroscopy, Chromatography), Measurement (On-Line, In-Line, At-Line), Products and Services (Analyzers, Probes & ... to 2021", published by MarketsandMarkets, the global market is poised to reach ... a CAGR of 13.3% from 2016 to 2021. ... ...
Breaking Medicine Technology: